Citigroup Inc Fibrogen Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Citigroup Inc holds 104 shares of FGEN stock, worth $36. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104

Previous 12,976 99.2%

Holding current value

$36

Previous $11,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.33 - $1.26 $4,247 - $16,218	-12,872 Reduced 99.2%	104 $0
Q2 2024 Aug 12, 2024	SELL	$0.89 - $2.36 $4,106 - $10,889	-4,614 Reduced 26.23%	12,976 $11,000
Q1 2024 May 10, 2024	SELL	$0.73 - $2.73 $56,918 - $212,858	-77,970 Reduced 81.59%	17,590 $41,000
Q4 2023 Feb 09, 2024	BUY	$0.38 - $0.91 $14,660 - $35,108	38,581 Added 67.71%	95,560 $85,000
Q3 2023 Nov 09, 2023	SELL	$0.79 - $2.83 $164,546 - $589,452	-208,287 Reduced 78.52%	56,979 $49,000
Q2 2023 Aug 10, 2023	SELL	$2.49 - $20.59 $822,842 - $6.8 Million	-330,459 Reduced 55.47%	265,266 $716,000
Q1 2023 May 11, 2023	BUY	$15.95 - $25.18 $2.22 Million - $3.5 Million	139,080 Added 30.46%	595,725 $11.1 Million
Q4 2022 Feb 09, 2023	SELL	$13.27 - $17.73 $992,954 - $1.33 Million	-74,827 Reduced 14.08%	456,645 $7.32 Million
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $555,043 - $710,844	48,688 Added 10.08%	531,472 $6.92 Million
Q2 2022 Aug 10, 2022	BUY	$7.94 - $12.96 $3.43 Million - $5.6 Million	431,957 Added 849.86%	482,784 $5.1 Million
Q1 2022 May 12, 2022	SELL	$12.02 - $16.79 $2.11 Million - $2.94 Million	-175,254 Reduced 77.52%	50,827 $610,000
Q4 2021 Feb 10, 2022	BUY	$9.93 - $15.39 $357,539 - $554,132	36,006 Added 18.94%	226,081 $3.19 Million
Q3 2021 Nov 10, 2021	BUY	$10.18 - $26.64 $1.93 Million - $5.06 Million	190,075 New	190,075 $1.94 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account